Metformin improves glucose effectiveness, not insulin sensitivity: Predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1870-1878

  Pau, Cindy T ^a   Keefe, Candace ^a   Duran, Jessica ^a   Welt, Corrine K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHORIONIC GONADOTROPIN; GLUCOSE; INSULIN; METFORMIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PREDICTION; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84899895236     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4021     Document Type: Article

References (56)

1. Knochenhauer ES, Key TJ , Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84: 4006-4011.
3. Asunció n M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF.Aprospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from S pain. J Clin Endocrinol Metab. 2000;85:2434-2438.
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.
5. Ch ang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-359.
6. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulindependent diabetes mellitus. J Clin Invest. 1995;96:520-527.
7. Ehrmann DA Barnes RB Rosenfield RL Cavaghan MK Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome Diabetes Care. 1999 22: 141-146.
8. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled stud y in 254 affected women. J Clin Endocrinol Metab. 1999;84: 165-169.
9. Welt CK, Arason G, Gudmundsson JA, et al. Defining constant versus variable phenotypic features of women with polycystic ova ry syndrome using different ethnic groups and populations. J Clin Endocrinol Metab. 2006;91:4361-4368.
10. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the me tabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-1935.
11. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48-53.
12. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17-activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.NEngl J Med. 1996; 335:617-623.
13. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-1880.
14. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metf ormin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility [published online May 16, 2012]. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003053.pub5.
15. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
16. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 1999; 48:2414-2421.
17. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J C lin Endocrinol Metab. 1997;82:524-530.
18. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138: 269-27 4.
19. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scie ntific; 1992:377-384.
20. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248-2256.
21. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a p rospective study. Fertil Steril. 1999;72:915-925.
22. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in dia betic subjects. J Clin Endocrinol Metab. 1990;71:1508-1518.
23. Welt CK, Adams JM, Sluss PM, Hall JE. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. J Clin Endocrinol Metab. 1999;84:2163-2169.
24. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled int ravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
25. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest. 2010;120:2267-2270.
26. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632-640.
27. Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 1987;10:62-67.
28. Owen MR, Do ran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348:607-614.
29. El-Mir MY Nogueira V Fontaine E Avéret N Rigoulet M Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I J Biol Chem. 2000 275 223-228.
30. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256-260.
31. Bergma n RN. Lilly Lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989;38:1512-1527.
32. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
33. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of theLKB1/AMPKpathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355-2369.
34. Hardie DG, Carling D, Ca rlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cellAnnu Rev Biochem. 1998;67:821-855.
35. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMPactivated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074-2081.
36. Zierath JR, Galuska D, Nolte LA, Thörne A, Kristensen JS, Wallberg-H enriksson H. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients withNIDDM:in vitro reversal of muscular insulin resistance. Diabetologia. 1994;37:270-277.
37. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest. 1992;90:1386-1395.
38. Brunzell JD, Robe rtson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976;42: 222-229.
39. Savage PJ, Bennion LJ, Flock EV, et al. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab. 1979;48:999-1007.
40. Açbay O, Gündodu S. Can metformin reduce insulin resistance in polycystic ovary syndrome Fertil Steril. 1996;65:946-949.
41. Palomba S, Falbo A, Russo T, et al. Insulin sensi tivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:3128-3135.
42. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
43. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
44. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139-146.
45. Essah PA, Apridonidze T, Iuorno MJ, Nestler JE. Effects of shortte rm and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril. 2006;86:230-232.
46. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:569-574.
47. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17-activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075-4079.
48. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-566.
49. Maciel GA, Soares Jú nior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment wit h metformin. Fertil Steril. 2004;81:355-360.
50. Baillargeon JP Jakubowicz DJ Iuorno MJ Jakubowicz S Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonob ese women with polycystic ovary syndrome and normal indices of insulin sensitivity Fertil Steril. 2004 82 893-902.
51. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003; 79:956-962.
52. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril. 2001;76:517-524.
53. Hirsch A, Hahn D, Kempn á P, et al. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory c hain. Endocrinology. 2012;153:4354-4366.
54. Rodrí guez-Moctezuma JR, Robles-López G, López-Carmona JM, Gutiérrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk fact ors for type 2 diabetes. Diabetes Obes Metab. 2005;7:189-192.
55. Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34:2381-2386.
56. la Marca A, Egbe TO, Morgante G, et al. Metformin treatment reduces ovarian cytochrome P-450c17-response to human chorionic gonadotrophin in women with insulin resi stance-related polycystic ovary syndrome. Hum Reprod. 2000;15:21-23.